key: cord-0793696-qxypmwmo authors: Specht, Aubrey G.; Kurtz, Sherry L.; Elkins, Karen L.; Specht, Harrison; Beamer, Gillian title: BCG vaccination of Diversity Outbred mice induces cross-reactive antibodies to SARS-CoV-2 spike protein date: 2022-04-19 journal: bioRxiv DOI: 10.1101/2022.04.18.488640 sha: 5bf2dfbc16f346b99c339000c6d8c376130343e3 doc_id: 793696 cord_uid: qxypmwmo The Bacillus Calmette-Guérin (BCG) vaccine, the only vaccine against tuberculosis, induces cross-protection against pathogens unrelated to Mycobacterium, including viruses. Epidemiological studies have identified potential benefits of BCG vaccination against SARS-CoV-2 infection. While BCG’s heterologous effects have been widely attributable to trained immunity, we hypothesized BCG vaccination could induce cross-reactive antibodies against the spike protein of SARS-CoV-2 Wuhan-Hu-1. The concentration of IgG reactive to SARS-CoV-2 spike protein from the sera of BCG-vaccinated, Diversity Outbred (DO) mice and C57BL/6J inbred mice was measured using ELISA. Sera from 10/15 BCG-vaccinated DO mice possessed more IgG reactive to recombinant spike protein than sera from BCG-vaccinated C57BL/6J mice and unvaccinated DO mice. Amino acid sequences common to BCG cell wall/membrane proteins and SARS-CoV-2 spike protein were identified as potential antigen candidates for future study. These results imply a humoral mechanism, influenced by genotype, by which BCG vaccination could confer immunity to SARS-CoV-2. Graphic Abstract Cross-Protective Benefits of the BCG vaccine. Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis and used to vaccinate 130 million children in 154 countries each year against tuberculosis (TB) [1] . However, BCG's impact extends beyond TB. Starting in 1927, epidemiological and basic research indicates that immunity induced by BCG confers cross-protection against other pathogens, including viruses [2, 3] . The SARS-CoV-2 virus did not affect countries equally. During the early months of the pandemic, epidemiological analyses showed that a 10% increase in BCG index, an estimate for a country's BCG vaccination use, was associated with a 10.4% decrease in COVID-19 mortality [4] . This intriguing finding led to clinical trials, seeking prospective validation. In the phase III trial ACTIVATE (NCT03296423), BCG revaccination of elderly patients (> 65 years) yielded 68% risk reduction for total COVID-19 clinical and microbiological diagnoses in the 6 months following vaccination [5] . On-going phase III clinical trials, such as BRACE (NCT04327206) and BATTLE (NCT04369794), are assessing BCG's protection against SARS-CoV-2 infection and its use as a therapeutic tool in patients currently infected with SARS-CoV-2, respectively [6] . Proposed mechanisms for BCGs cross-protection include: 1) trained immunity of the innate immune system, driven by monocytes and natural killer (NK) cells; 2) T cell lymphocyte-dependent activation of innate immunity and adaptive immunity; and 3) antibody cross-reactivity to a wide array of antigens [1] . Humoral Immunity's Role in Preventing Infection. To infect host cells, SARS-CoV-2's surface spike glycoproteins bind the angiotensin-converting enzyme 2 (ACE-2) receptors on host cells [7] . Neutralizing antibodies prevent this initial binding [8] , demonstrating a role for B-cell derived (humoral) immunity against SARS-CoV-2. The role B cells and antibodies play in the cross-protective benefits of BCG against SARS-CoV-2 is currently debated. In silico analysis has found 690 BCG B-cell epitopes similar to SARS-CoV-2 B-cell epitopes, including epitopes in the RBD of the spike protein [9] . Using immunohistochemistry, another study found that an antibody directed against the SARS-CoV-2 envelope protein also bound the LytR C protein found in M. bovis [10] . However, results from an in vivo study in the BALB/c inbred mouse strain appear contradictory, as BCG vaccination did not produce cross-reactive neutralizing antibodies against SARS-CoV-2 [11] . Here, we investigated BCG-induced antibodies against SARS-CoV-2 spike glycoprotein. In silico analysis showed homology between predicted antibody epitopes on the SARS-CoV-2 Spike protein and the proteome of BCG. Further, we measured cross-reactive antibodies to the SARS-CoV-2 Spike protein in different mouse strains (i.e., Diversity Outbred (DO) mice and C57BL/6J inbred mice). We compared the level of SARS-CoV-2 reactive antibodies in the sera of BCG-vaccinated, outbred Diversity Outbred (DO) and inbred C57BL/6J mice with the sera of unvaccinated DO mice. In Silico Analysis of Homology: Bepipred Linear Epitope Prediction 2.0 from IEBD was used to select predicted antibody binding epitopes (>5 amino acids long) on the SARS-CoV-2 spike protein (SwissProt: P0DTC2). Basic Local Alignment Search Tool (BLAST) from NCBI was used to align the selected epitopes with the Swiss-Prot reviewed proteome of BCG strain Pasteur (Mycobacterium bovis (strain BCG / Pasteur 1173P2). The results were restricted to only matches with >70% ID and alignment length ≥7 amino acids, based on previous research on homologous peptide length and T cell activation [12] . Pentamers with 100% ID and 6-mer with 83.3% ID were also included, because antibody epitopes can range from 4-12 amino acids [13] . The BCG protein and cellular component, as described on the UniprotKB database, was obtained for each peptide fitting the above criteria. were used at 6-10 weeks of age. All mice were housed in groups by strain in microisolator cages and given autoclaved food and water ad libitum. A single, frozen vial of BCG was thawed and diluted in sterile PBS. Mice were vaccinated intradermally or intravenously with 10 5 BCG Pasteur colony forming units (Table 1) . Eight weeks later, mice were euthanized and blood was obtained via cardiac puncture with a heparinized 1 ml syringe and 26g needle. Sera were separated using Sarstedt microtubes (Fisher Scientific, Pittsburg, PA) [14] , stored at -80 o C and shipped from Food and Drug Administration (Silver Spring, MD) to Cummings School of Veterinary Medicine (Grafton, MA) for assays. Unvaccinated mice. All procedures on live mice were approved by Tufts University's Institutional Animal Care and Use Committee (IACUC) protocols G2015-33 or G2018-02, or the CEBR/FDA protocol #2011-14. Female DO mice, purchased from Jackson Laboratories, were housed socially, and provided sterile food and water ad libitum. Unvaccinated mice received no treatment. Mice were euthanized, blood was collected via cardiac puncture, allowed to clot, centrifuged and serum collected, and stored at -80 o C until use (Table 1) . 18 We optimized an in-house ELISA to detect cross-reactive IgG antibodies in mouse sera. On day 1, Costar 96-well plates were coated in 1 µg/mL recombinant SARS-CoV-2 Spike protein ("rSpike," BEI Resources NR-52308) diluted in PBS. Half of the plate was left uncoated to measure nonspecific interactions [15] . Assay control: On each plate, an independent assay control was run to assess the quality of the detection antibody and colorimetric reaction, as follows: On day 1, the well was coated with 5 µg/mL of a mixture containing recombinant ESAT-6 and CFP-10 (BEI Resources NR-49424, NR-49425). On day 2, sera from CFP-10-vaccinated mice, diluted 1:100 in 1% BSA, were incubated in the well. On day 3, the same detection antibody, goat anti-mouse IgG-HRP, was added followed by the addition of TMB and then HCl, as described above. Statistical Analysis: Graphs were made using Prism GraphPad version 9.1.0. Standard curve limit of detection was calculated based on the sum of the mean blank optical density and three times the standard deviation based on 6 blanks. Histograms and Student's t-tests were performed using R. Early in the COVID-19 pandemic, epidemiological evidence suggested cross-protection between the BCG vaccine and SARS-CoV-2 infection, fueling investigation into possible mechanisms such as cross-reactive antibodies. Potential cross-reactive antibody binding sites were predicted by in silico comparison of proteins' cellular components were described, if known. The frequency of the cellular components was described. 1c. Homologous peptides restricted to BCG proteins located on the cell surface. The five BCG Pasteur proteins known to be located on the cell surface from 1b were identified and their sequences compared with the SARS-CoV-2 Spike protein. The concentration of IgG binding SARS-CoV-2 rSpike protein was compared between Diversity Outbred mice vaccinated with BCG, C57BL/6J mice vaccinated with BCG, and unvaccinated Diversity Outbred mice (Figure 2 ). Sera from BCG-vaccinated C57BL/6J mice (n=10) were compared with sera from BCG-vaccinated DO mice (n=15) and unvaccinated DO mice (n=5). The signal from uncoated wells incubated with the sera was undetectable. As the unvaccinated DO mice have not been challenged by any pathogen, the signal and resulting concentration of IgG produced by the ELISA is a presumed noise, due to non-specific interactions between normal serum components with assay reagents. cross-reactive neutralizing antibodies against SARS-CoV-2 using the inbred BALB/c strain [11] . Future research could explore this study's limitations by characterizing the binding site of the cross-reactive IgG antibodies and assessing the antibodies for neutralizing efficacy, or by investigating the genetic basis for the cross-reactive humoral response in DO mice. To the first point, affinity purification mass spectrometry (AP-MS) could confirm antibody concentration and purify the cross-reactive antibodies for affinity testing against peptides identified by our in silico analysis. To the second point, genotype-phenotype association studies, such as quantitative trait locus mapping, could be performed on larger sample sizes to identify gene candidates and polymorphisms. Using an ELISA, we found that a subgroup of BCG-vaccinated Diversity Outbred mice produced a concentration of cross-reactive IgG antibodies to the spike protein on SARS-CoV-2 above that of unvaccinated mice, and interestingly BCG-vaccinated inbred C57BL/6J mice. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny Shared antigens between heterologous bacterial species 100 years of Mycobacterium bovis bacille Calmette-Guérin BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) Activate-2: a double-blind randomized trial of BCG vaccination against COVID19 in individuals at risk The BCG Vaccine for COVID-19: First Verdict and Future Directions Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor The Humoral Immune Response to BCG Vaccination Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive adaptive immunity Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2 Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays The Diversity Outbred Mouse Population Is an Improved Animal Model of Vaccination against Tuberculosis That Reflects Heterogeneity of Protection. mSphere An ELISA protocol to improve the accuracy and reliability of serological antibody assays High-resolution genetic mapping using the Mouse Diversity outbred population Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2